Advertisement

Topics

Dako Incorporated Company Profile

08:44 EST 18th November 2017 | BioPortfolio

Identification of the origins of tumors and other diseases in body tissues has made great strides over the past two decades. As researchers expand their knowledge of cellular antigens and how these antigens are associated with various disorders, more accurate diagnoses can be made, leading to more effective patient treatments. Immunohistochemistry plays a key role in this process. It is this area in which DAKO is recognized as the world's leading supplier of reagents and staining systems.

DAKO continually expands its list of over 2000 monoclonal and polyclonal antibodies, complemented by a plethora of immunohistochemical staining kits, applicable for routine and advanced clinical and research use. With the introduction of an automated staining platform, DAKO is continually renewing its commitment to provide cost effective, comprehensive and time saving products to customers, to assist them in the most accurate testing and interpretation available.

Location

6392 Via Real
Carpinteria
CA
93013
United States of America

Contact

Phone: 805-566-6655
Fax: 805-566-1344


News Articles [9 Associated News Articles listed on BioPortfolio]

Vical Incorporated Announces Pricing of $25 Million Underwritten Public Offering of Common Stock

SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the pricing of its underwritten public offering of 14,285,714 shares of common stock or common stock ...

Proscia Provides Agilent Technologies with Digital Pathology Platform for Interactive Version of the Dako Atlas of Stains

The cloud-based Atlas of Stains trains pathologists and histotechnicians on using and interpreting stained pathology tissue samples, provides reference for interpretation of results. Baltimore, MD (PR...

PTV News: Jan 19, 2010

Top stories on January 19th, 2010: Enemy Alli – FDA warns of counterfeit weight loss drug Getting personal – AstraZeneca’s diagnostics deal with Dako Teva and Pfizer "last contenders" in battle...

Agilent Receives Expanded FDA Approval For The Use Of Dako PD-L1 IHC 22C3 Pharmdx Companion Diagnostic In Gastric Or Gastroesophageal Junction (GEJ) Cancer

Patients with gastric or GEJ adenocarcinoma whose tumors express PD-L1 can now be identified for potential treatment with KEYTRUDA (pembrolizumab) using PD-L1 IHC 22C3 pharmDx SAN...

Agilent Announces Expanded Use of Cancer Diagnostic in the United States

Dako PD-L1 IHC 28-8 PharmDx Approved for Two New Indications Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved ...

CORRECTING and REPLACING Agilent Technologies Receives Expanded FDA Approval for the Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Gastric or Gastroesophageal Junction (GEJ) Cancer

Patients with gastric or GEJ adenocarcinoma whose tumors express PD-L1 can now be identified for potential treatment with KEYTRUDA® (pembrolizumab) using PD-L1 IHC 22C3 pharmDx ...

Agilent Technologies Receives Expanded FDA Approval for the Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Gastric or Gastroesophageal Junction (GEJ) Cancer

Patients with gastric or GEJ adenocarcinoma whose tumors express PD-L1 can now be identified for potential treatment with KEYTRUDA® (pembrolizumab) using PD-L1 IHC 22C3 pharmDx ...

Dako AS Medical Equipment Deals and Alliances Profile [Report Updated: 12072017] Prices from USD $250

SummaryDako A/S Dako Denmark, a subsidiary of Agilent Technologies Inc is a diagnostic company. The company's products include diagnostic antibodies, reagents and kits, software related products, inst...

PubMed Articles [8 Associated PubMed Articles listed on BioPortfolio]

Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.

For non-small cell lung cancer (NSCLC), treatment with pembrolizumab is limited to patients with tumours expressing PD-L1 assessed by immunohistochemistry (IHC) using the PD-L1 IHC 22C3 pharmDx (Dako,...

Epistatic interaction between the lipase-encoding genes Pnpla2 and Lipe causes liposarcoma in mice.

Liposarcoma is an often fatal cancer of fat cells. Mechanisms of liposarcoma development are incompletely understood. The cleavage of fatty acids from acylglycerols (lipolysis) has been implicated in ...

Diagnostic utility of automated SureFISH (Dako Omnis) in the diagnosis of musculoskeletal translocation-related sarcomas.

Fluorescence in situ hybridization (FISH) is an essential tool for genetic diagnosis in daily pathological work. Almost full automation of FISH can be achieved with the recently released automated Sur...

PD-L1 in Breast Cancer: Comparative Analysis of Three Different Antibodies.

The Programmed cell death-1 and its ligand-1 (PD-L1) interaction serve as a regulatory check against excessive immune response to antigen and autoimmunity. We compared the performance of three differe...

Making of a Synapse: Recurrent Roles of Drebrin A at Excitatory Synapses Throughout Life.

Mature excitatory synapses are composed of more than 1500 proteins postsynaptically and hundreds more that operate presynaptically. Among them, drebrin is an F-actin-binding protein that increases not...

Clinical Trials [0 Results]

None

Companies [42 Associated Companies listed on BioPortfolio]

Dako Incorporated

Identification of the origins of tumors and other diseases in body tissues has made great strides over the past two decades. As researchers expand their knowledge of cellular antigens and how these an...

Dako Denmark A/S

Dako is one of the world's leading companies in cancer diagnostics. We are devoted to helping pathologists by improving their ability to diagnose cancer. To do this, we develop, manufacture and market...

DAKO JAPAN Company Limited

Diagnostics Laboratory Animals

Dako Australia

makers of automated, predictive,diagnostic, and prognostic cancer systems.

DAKO

A Danish company with over 1,000 products related to antibodies and antibody technology, including clinical immunohistochemistry, flow cytometry, immunocytochemistry, hybridization, microbiology, prim...

More Information about "Dako Incorporated" on BioPortfolio

We have published hundreds of Dako Incorporated news stories on BioPortfolio along with dozens of Dako Incorporated Clinical Trials and PubMed Articles about Dako Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Dako Incorporated Companies in our database. You can also find out about relevant Dako Incorporated Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record